This site is for U.S. Healthcare Professionals Only
Hyperphosphatemia CKD On Dialysis
Hyperphosphatemia CKD On Dialysis

Sign up to get the latest news and resources for you and your patients

Complete the form below to get access to the latest information on AURYXIA and other updates from Akebia.

Fields marked with an asterisk (*) are required.

Need your NPI number? Look it up here.

Your NPI number must be in your name and not shared across your facility or in the name of any other person. If you are a healthcare professional and you do not have an NPI number in your name, select the checkbox below.

By providing my information above, I agree to the Akebia Therapeutics, Inc. (“Akebia”) Privacy Policy and give Akebia, its affiliates, and business partners permission to contact me via email for marketing purposes or otherwise provide me with information about company products, services, and programs or other topics of interest, conduct market research, or otherwise ask me about my experience with or thoughts about such topics. Akebia will not sell or transfer my information to any unrelated third party for marketing purposes without my express permission. I may opt out at any time by clicking the unsubscribe link within any email I receive.

To find your NPI number, please fill out the information below.

Fields marked with an asterisk (*) are required.

No results found

Refine your search and try again.

Search Results

Select the entry with your name and address information. If you cannot find your information from these results, please cancel and register without an NPI number.

Name NPI number State ZIP code


AURYXIA® (ferric citrate) is indicated for:

  • The control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis

Important Safety Information


AURYXIA® (ferric citrate) is contraindicated in patients with iron overload syndromes, e.g., hemochromatosis

Warnings and Precautions

  • Iron Overload: Increases in serum ferritin and transferrin saturation (TSAT) were observed in clinical trials with AURYXIA in patients with chronic kidney disease (CKD) on dialysis treated for hyperphosphatemia, which may lead to excessive elevations in iron stores. Assess iron parameters prior to initiating AURYXIA and monitor while on therapy. Patients receiving concomitant intravenous (IV) iron may require a reduction in dose or discontinuation of IV iron therapy
  • Risk of Overdosage in Children Due to Accidental Ingestion: Accidental ingestion and resulting overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Advise patients of the risks to children and to keep AURYXIA out of the reach of children

Adverse Reactions

The most common adverse reactions reported with AURYXIA in clinical trials were:

  • Hyperphosphatemia in CKD on Dialysis: Diarrhea (21%), discolored feces (19%), nausea (11%), constipation (8%), vomiting (7%) and cough (6%)

Specific Populations

  • Pregnancy and Lactation: There are no available data on AURYXIA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. However, an overdose of iron in pregnant women may carry a risk for spontaneous abortion, gestational diabetes and fetal malformation. Data from rat studies have shown the transfer of iron into milk, hence, there is a possibility of infant exposure when AURYXIA is administered to a nursing woman

To report suspected adverse reactions, contact Akebia Therapeutics, Inc. at 1-844-445-3799

Please see full Prescribing Information